Cantor Fitzgerald Comments on ALX Oncology FY2024 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Stock analysts at Cantor Fitzgerald raised their FY2024 earnings per share estimates for ALX Oncology in a report released on Tuesday, November 12th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings per share of ($2.69) for the year, up from their previous forecast of ($3.08). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.86) per share.

Several other equities analysts have also recently weighed in on ALXO. Stifel Nicolaus restated a “hold” rating and set a $3.00 price objective (down from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. UBS Group dropped their price objective on ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 16th. Lifesci Capital lowered shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a research note on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, ALX Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $12.50.

ALX Oncology Stock Performance

Shares of ALXO opened at $1.33 on Friday. ALX Oncology has a 12 month low of $1.30 and a 12 month high of $17.83. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The firm’s fifty day simple moving average is $1.72 and its two-hundred day simple moving average is $5.71. The stock has a market capitalization of $70.14 million, a P/E ratio of -0.45 and a beta of 1.03.

Institutional Trading of ALX Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of ALXO. CANADA LIFE ASSURANCE Co bought a new position in ALX Oncology in the 1st quarter valued at approximately $27,000. EntryPoint Capital LLC bought a new stake in ALX Oncology in the 1st quarter worth about $32,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after buying an additional 5,200 shares during the last quarter. SG Americas Securities LLC lifted its stake in ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after acquiring an additional 6,888 shares during the period. Finally, Hsbc Holdings PLC purchased a new stake in shares of ALX Oncology during the 2nd quarter valued at about $63,000. 97.97% of the stock is currently owned by institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.